Geron resumed with a Sell at Goldman Sachs

Goldman Sachs resumed coverage of Geron (GERN) with a Sell rating and $1 price target which suggests 31% downside. The initial launch of the company’s lead product and first commercial drug, Rytelo, has disappointed, and the near-term trajectory for the launch will be modest, the analyst tells investors in a research note.